We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Rotavirus antibody (2B4)
Intermediate capsid protein VP6
Gene name: VP6
Gene name: VP6
As low as
$306.10
In stock
Ref
00012745
Intermediate capsid protein that self assembles to form an icosahedral capsid with a T=13 symmetry, which consists of 230 trimers of VP6, with channels at each of its five-fold vertices. This capsid constitutes the middle concentric layer of the viral mature particle. The innermost VP2 capsid and the intermediate VP6 capsid remain intact following cell entry to protect the dsRNA from degradation and to prevent unfavorable antiviral responses in the host cell during all the replication cycle of the virus.
| ID Covalab | mab0036-P |
|---|---|
| Product type | Primary antibodies |
| Clonality | Monoclonal antibody |
| Clone | 2B4 |
| Isotype | IgG2b / Kappa |
| Raised in | Mouse |
| Immunogen | Recombinant inner capsid protein (VP6) |
| Activity cross reaction | Reacts with human 41 kDa inner capsid protein (VP6) of Rotavirus (RV). |
| Species | RoV |
| Labelling | None |
| Form | Purified (protein A) |
| Preservative | None |
| Storage instructions | Lyophilized powder stable for a minimum of 2 years at -20°C. Store reconstituted antibodies at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt. |
| Target | inner capsid protein (VP6) of Rotavirus |
| Uniprot ID | P04509 |
| Gene ID | 7011372 |
| Applications | ICC, IF, WB |
| Working dilutions | Optimal dilution should be determined by the end user. The following are guidelines only : ICC/IF (1:100 - 1:500) WB (1:200 - 1:1 000) |
| Publication | * Civra A et al. J Steroid Biochem Mol Biol. 2019 Jul 11:105424 * Cagno V et al. PLoS One. 2018 Dec 7:13(12):e0208333 * D Lembo, GLGE Poli, A Civra, V Cagno - US Patent App. 15/877,831, 2018 * Civra A et al. Redox Biol. 2018, 19:318-30. * Lembo D et al. Oxysterols for use in the treatment and prevention of diseases caused by viruses. US Patent Application 20170137458 * Cagno V et al. J Ethnopharmacol. 2015 May 26,166:129-34. * Lembo D et al. Eur J Pharm Biopharm. 2014 Sep,88(1):275-82. * Morrison T. Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines. US Patent 20,140,134,203, 2014 |
Write Your Own Review